# A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated

> **NCT04863638** · PHASE4 · UNKNOWN · sponsor: **China National Biotec Group Company Limited** · enrollment: 4400 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** 3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated
- **BIOLOGICAL:** 3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated
- **BIOLOGICAL:** 3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated
- **BIOLOGICAL:** 2 doses of vaccine

## Key facts

- **NCT ID:** NCT04863638
- **Lead sponsor:** China National Biotec Group Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-29
- **Primary completion:** 2021-12-20
- **Final completion:** 2024-03-31
- **Target enrollment:** 4400 (ACTUAL)
- **Last updated:** 2023-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04863638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04863638, "A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04863638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*